Results 11 to 20 of about 1,579,650 (291)

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export

open access: yesOncoImmunology, 2020
Therapeutic monoclonal antibodies against the PD-L1/PD-1 (programmed death ligand-1/programmed cell death protein-1) axis have achieved great successes in cancer treatments, but the development of small-molecule immunomodulators of the pathway has lagged
Fang-Fang Chen   +3 more
doaj   +1 more source

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

open access: yes, 2023
Acute respiratory distress syndrome (ARDS) is a severe lung condition with a high mortality rate and a lack of effective drug therapy. In this work, we developed mesenchymal stem cell (MSC)-derived extracellular vesicles with high PD-L1 expression (MSC ...
Ting Lu (149031)   +10 more
core   +1 more source

Identification of a Small Molecule that Binds to the PD-L1 Dimer Interface [PDF]

open access: yes, 2023
In recent years, antibody drugs targeting PD-1/PD-L1 immune checkpoints have shown immense clinical benefits in cancer treatment. However, these drugs suffer from poor patient tolerance, large and difficult-to-control adverse reactions, insufficient oral
Hengwei, Bian   +11 more
core   +1 more source

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

open access: yesEJNMMI Research, 2020
Background Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors.
Sheng Zhao   +6 more
doaj   +1 more source

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.

open access: yesPLoS ONE, 2020
Programmed death-1 (PD-1) is an immunoinhibitory receptor expressed on lymphocytes. Interaction of PD-1 with its ligand PD-ligand 1 (PD-L1) delivers inhibitory signals and impairs proliferation, cytokine production, and cytotoxicity of T cells.
Otgontuya Ganbaatar   +14 more
doaj   +1 more source

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

open access: yesCell Death and Disease, 2022
Immune checkpoint molecule programmed death-ligand 1 (PD-L1) is overexpressed in cancer cells and imparts resistance to cancer therapy. Although membrane PD-L1 has been targeted for cancer immune therapy, nuclear PD-L1 was reported to confer cancer ...
Je-Jung Lee   +5 more
doaj   +1 more source

Image_1_Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.tif

open access: yes, 2022
The contribution of natural killer (NK) cells to tumor rejection in the context of programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) blockade is a matter of intense debate.
Maria-Luisa del Rio (12894632)   +5 more
core   +1 more source

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

open access: yesCancer Medicine, 2020
Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains ...
Yuka Suzuki   +11 more
doaj   +1 more source

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD‐1/PD‐L1 inhibitors: A systematic review and meta‐analysis

open access: yesCancer Medicine, 2023
Background and Aim Programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors have transformed the treatment landscape of advanced hepatocellular carcinoma (HCC), but consistent responses are not observed in all patients, and prognostic ...
Yao Yang   +6 more
doaj   +1 more source

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma [PDF]

open access: yesJournal of Thoracic Disease, 2020
Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained.
Yokoyama, Shintaro, Miyoshi, Hiroaki
openaire   +2 more sources

Home - About - Disclaimer - Privacy